Sanofi (NYSE: SNY) announced today the successful completion of its acquisition of Bioverativ Inc. ("Bioverativ") for $105 per share in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE